Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS)
NCT04925024Phase 2Active, not recruiting
- Sponsor
- Longeveron
- Start
- Jun 2021
- Primary completion
- Jun 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of laromestrocel in hypoplastic left heart syndrome (HLHS) (2 arms), sponsored by Longeveron. Primary endpoint: Change in right ventricular ejection fraction at 12 months. Started Jun 2021; status: active, not recruiting.
02
Drugs
laromestrocel
03
Conditions
hypoplastic left heart syndrome (HLHS)
Beyond the preview
Go deeper on NCT04925024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925024.